B. Immunotherapy and kidney transplant

Kiran Shivaraj; Ala Abudayyeh; A. Osama Gaber

doi:10.1016/B978-0-443-21901-6.00009-4

B. Immunotherapy and kidney transplant

Kiran Shivaraj, Ala Abudayyeh, A. Osama Gaber

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

With the expansive use of Immune checkpoint inhibitors (ICI) from different cancers to neoadjuvant, more challenges have been associated with management of immune adverse events. Use of ICI in organ transplant patients especially the kidney is an “unmet need” because of increased risk of rejection. Understanding the increased risk of rejection in organ transplant patients and the proposed possible mechanisms is of importance to further develop guidelines for such a population. Based on the limited retrospective studies and few clinical trials we will attempt to draw recommendations in management of kidney transplant patients with cancer and the need for ICI treatment.

Original language	English (US)
Title of host publication	Transplant Oncology
Subtitle of host publication	A Frontier in Multidisciplinary Cancer Care
Publisher	Elsevier
Pages	107-113
Number of pages	7
ISBN (Electronic)	9780443219016
ISBN (Print)	9780443219023
DOIs	https://doi.org/10.1016/B978-0-443-21901-6.00009-4
State	Published - Jan 1 2024

Keywords

Acute kidney injury
Allograft rejection
CTLA-4
Immune checkpoint inhibitor
Immunotherapy
Interstitial nephritis
Kidney transplantation
PD1
Solid organ transplant

ASJC Scopus subject areas

General Agricultural and Biological Sciences
General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/B978-0-443-21901-6.00009-4

Cite this

@inbook{090dfe7cf197465fa5f22fd477f5a64c,

title = "B. Immunotherapy and kidney transplant",

abstract = "With the expansive use of Immune checkpoint inhibitors (ICI) from different cancers to neoadjuvant, more challenges have been associated with management of immune adverse events. Use of ICI in organ transplant patients especially the kidney is an “unmet need” because of increased risk of rejection. Understanding the increased risk of rejection in organ transplant patients and the proposed possible mechanisms is of importance to further develop guidelines for such a population. Based on the limited retrospective studies and few clinical trials we will attempt to draw recommendations in management of kidney transplant patients with cancer and the need for ICI treatment.",

keywords = "Acute kidney injury, Allograft rejection, CTLA-4, Immune checkpoint inhibitor, Immunotherapy, Interstitial nephritis, Kidney transplantation, PD1, Solid organ transplant",

author = "Kiran Shivaraj and Ala Abudayyeh and Gaber, {A. Osama}",

year = "2024",

month = jan,

day = "1",

doi = "10.1016/B978-0-443-21901-6.00009-4",

language = "English (US)",

isbn = "9780443219023",

pages = "107--113",

booktitle = "Transplant Oncology",

publisher = "Elsevier",

address = "United States",

}

TY - CHAP

T1 - B. Immunotherapy and kidney transplant

AU - Shivaraj, Kiran

AU - Abudayyeh, Ala

AU - Gaber, A. Osama

PY - 2024/1/1

Y1 - 2024/1/1

N2 - With the expansive use of Immune checkpoint inhibitors (ICI) from different cancers to neoadjuvant, more challenges have been associated with management of immune adverse events. Use of ICI in organ transplant patients especially the kidney is an “unmet need” because of increased risk of rejection. Understanding the increased risk of rejection in organ transplant patients and the proposed possible mechanisms is of importance to further develop guidelines for such a population. Based on the limited retrospective studies and few clinical trials we will attempt to draw recommendations in management of kidney transplant patients with cancer and the need for ICI treatment.

AB - With the expansive use of Immune checkpoint inhibitors (ICI) from different cancers to neoadjuvant, more challenges have been associated with management of immune adverse events. Use of ICI in organ transplant patients especially the kidney is an “unmet need” because of increased risk of rejection. Understanding the increased risk of rejection in organ transplant patients and the proposed possible mechanisms is of importance to further develop guidelines for such a population. Based on the limited retrospective studies and few clinical trials we will attempt to draw recommendations in management of kidney transplant patients with cancer and the need for ICI treatment.

KW - Acute kidney injury

KW - Allograft rejection

KW - CTLA-4

KW - Immune checkpoint inhibitor

KW - Immunotherapy

KW - Interstitial nephritis

KW - Kidney transplantation

KW - PD1

KW - Solid organ transplant

UR - http://www.scopus.com/inward/record.url?scp=85215996923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85215996923&partnerID=8YFLogxK

U2 - 10.1016/B978-0-443-21901-6.00009-4

DO - 10.1016/B978-0-443-21901-6.00009-4

M3 - Chapter

AN - SCOPUS:85215996923

SN - 9780443219023

SP - 107

EP - 113

BT - Transplant Oncology

PB - Elsevier

ER -

B. Immunotherapy and kidney transplant

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this